Načítá se...
Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration
Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however...
Uloženo v:
| Vydáno v: | BMJ Case Rep |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5775795/ https://ncbi.nlm.nih.gov/pubmed/29298794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-222851 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|